ArticleCellular and molecular neurobiology2025
Inhibition of P2Y6 Receptor-Mediated Microglia Phagocytosis Aggravates Brain Injury in Mice of Intracerebral Hemorrhage.
Article in Cellular and molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glial-mediated immune modulation in glaucomatous neurodegeneration: mechanisms and therapeutic implications.Frontiers in immunology · 2025Review
- Brain cell-released Cyclophilin A induces neuroinflammation and exacerbates blood-brain barrier injury in acute ischemic stroke.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Intracerebral hemorrhage (ICH) is a devastating stroke subtype leading to severe sensorimotor dysfunction. Many studies showed that microglia phagocytosis could promote hematoma absorption, and scavenger receptors expressed on microglia were associated with its phagocytosis. As a specific phagocytic receptor, blocking the P2Y6 receptor (P2Y6R) with MRS2578 (3 mg/kg) could inhibit the phagocytic activity of microglia, which had been reported in a variety of neurological disorders, such as cerebral ischemia, Parkinson's diseases and neurodegenerative diseases. But the effects of P2Y6R-mediated microglia phagocytosis on the prognosis of ICH are still lacking. In the present study, we showed that P2Y6R expression elevated and peaked at day 3 after ICH. And treatment with MRS2578 (3 mg/kg) for three consecutive days could impair the phagocytosis of microglia, accompanied by delayed hematoma absorption rate, aggravated brain edema and blood-brain barrier disruption, as well as impaired neurological deficit in ICH mice. MRS2578 treatment also increased the expression of pro-inflammatory factors (TNF-α, iNOS) after ICH. Furthermore, MRS2578 treatment further increased the expression of NF-κB, which regulates the expression of these pro-inflammatory cytokines. In summary, our results suggested that regulating microglial phagocytosis could improve the prognosis of ICH, and P2Y6R offered a meaningful target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.